Verapamil improves exercise capacity in chronic atrial fibrillation: Double-blind crossover study

Roberto Lang; Herman O. Klein; Elio Di Segni; Jacob Gefen; Pinhas Sareli; Carlos Libhaber; Daniel David; Eliyahu Weiss; Juan Guerrero; Elieser Kaplinsky

doi:10.1016/0002-8703(83)90246-6

Verapamil improves exercise capacity in chronic atrial fibrillation: Double-blind crossover study

Roberto Lang, Herman O. Klein^*, Elio Di Segni, Jacob Gefen, Pinhas Sareli, Carlos Libhaber, Daniel David, Eliyahu Weiss, Juan Guerrero, Elieser Kaplinsky

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

Oral verapamil has previously been shown to reduce heart rate at rest and during mild exercise in chronic atrial fibrillation. Its efficacy in improving cardiovascular performance at higher levels of exercise and its safety were investigated in a prospective, randomized, placebo controlled double-blind study preceded by an open label titration phase in 20 digitalized patients with chronic atrial fibrillation. Maximal exercise capacity was improved (from 522 ± 257 to 806 ± 348 work units, p < 0.0005) when tested by a standardized multistage ergometry exercise test. Heart rate was also reduced at rest, at the end of 3 minutes of 300 KPM exercise, and at the point of maximal exercise. Blood pressure and double product were also reduced. Its efficacy and safety may make verapamil the treatment of choice in chronic atrial fibrillation.

Original language	English
Pages (from-to)	820-825
Number of pages	6
Journal	American Heart Journal
Volume	105
Issue number	5
DOIs	https://doi.org/10.1016/0002-8703(83)90246-6
State	Published - May 1983

Access to Document

10.1016/0002-8703(83)90246-6

Cite this

@article{fd37087153284b948b4e7eccff2f2ee4,

title = "Verapamil improves exercise capacity in chronic atrial fibrillation: Double-blind crossover study",

abstract = "Oral verapamil has previously been shown to reduce heart rate at rest and during mild exercise in chronic atrial fibrillation. Its efficacy in improving cardiovascular performance at higher levels of exercise and its safety were investigated in a prospective, randomized, placebo controlled double-blind study preceded by an open label titration phase in 20 digitalized patients with chronic atrial fibrillation. Maximal exercise capacity was improved (from 522 ± 257 to 806 ± 348 work units, p < 0.0005) when tested by a standardized multistage ergometry exercise test. Heart rate was also reduced at rest, at the end of 3 minutes of 300 KPM exercise, and at the point of maximal exercise. Blood pressure and double product were also reduced. Its efficacy and safety may make verapamil the treatment of choice in chronic atrial fibrillation.",

author = "Roberto Lang and Klein, {Herman O.} and {Di Segni}, Elio and Jacob Gefen and Pinhas Sareli and Carlos Libhaber and Daniel David and Eliyahu Weiss and Juan Guerrero and Elieser Kaplinsky",

year = "1983",

month = may,

doi = "10.1016/0002-8703(83)90246-6",

language = "אנגלית",

volume = "105",

pages = "820--825",

journal = "American Heart Journal",

issn = "0002-8703",

publisher = "Mosby Inc.",

number = "5",

}

TY - JOUR

T1 - Verapamil improves exercise capacity in chronic atrial fibrillation

T2 - Double-blind crossover study

AU - Lang, Roberto

AU - Klein, Herman O.

AU - Di Segni, Elio

AU - Gefen, Jacob

AU - Sareli, Pinhas

AU - Libhaber, Carlos

AU - David, Daniel

AU - Weiss, Eliyahu

AU - Guerrero, Juan

AU - Kaplinsky, Elieser

PY - 1983/5

Y1 - 1983/5

N2 - Oral verapamil has previously been shown to reduce heart rate at rest and during mild exercise in chronic atrial fibrillation. Its efficacy in improving cardiovascular performance at higher levels of exercise and its safety were investigated in a prospective, randomized, placebo controlled double-blind study preceded by an open label titration phase in 20 digitalized patients with chronic atrial fibrillation. Maximal exercise capacity was improved (from 522 ± 257 to 806 ± 348 work units, p < 0.0005) when tested by a standardized multistage ergometry exercise test. Heart rate was also reduced at rest, at the end of 3 minutes of 300 KPM exercise, and at the point of maximal exercise. Blood pressure and double product were also reduced. Its efficacy and safety may make verapamil the treatment of choice in chronic atrial fibrillation.

AB - Oral verapamil has previously been shown to reduce heart rate at rest and during mild exercise in chronic atrial fibrillation. Its efficacy in improving cardiovascular performance at higher levels of exercise and its safety were investigated in a prospective, randomized, placebo controlled double-blind study preceded by an open label titration phase in 20 digitalized patients with chronic atrial fibrillation. Maximal exercise capacity was improved (from 522 ± 257 to 806 ± 348 work units, p < 0.0005) when tested by a standardized multistage ergometry exercise test. Heart rate was also reduced at rest, at the end of 3 minutes of 300 KPM exercise, and at the point of maximal exercise. Blood pressure and double product were also reduced. Its efficacy and safety may make verapamil the treatment of choice in chronic atrial fibrillation.

UR - http://www.scopus.com/inward/record.url?scp=0020530350&partnerID=8YFLogxK

U2 - 10.1016/0002-8703(83)90246-6

DO - 10.1016/0002-8703(83)90246-6

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

AN - SCOPUS:0020530350

SN - 0002-8703

VL - 105

SP - 820

EP - 825

JO - American Heart Journal

JF - American Heart Journal

IS - 5

ER -

Verapamil improves exercise capacity in chronic atrial fibrillation: Double-blind crossover study

Abstract

Access to Document

Other files and links

Fingerprint

Cite this